Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers develop new treatment to improve recovery after spinal cord injury
"This discovery is an exciting step in uncovering other possible combined treatments that have the potential to improve cell transplant therapy." Dr Jon Prager, RVC.

Teams create novel combined cellular and molecular treatment.

New research conducted by the Royal Veterinary College (RVC) in collaboration with the University of Bristol has led to the development of a new type of combined cell treatment that can help to improve recovery after spinal cord injury in companion animals and, ultimately, humans.

There is currently no cure for paralysis caused by damage to nerves in the spine, however, it is possible to inject cells from the nose – called olfactory ensheathing cells – into these damaged nerves. This has shown to improve walking in both experimental and companion animals and, though it is also known to be safe for humans, it has not been tested in a full clinical trial.

Another potential treatment is the injection of a molecule called chondroitinase. This has also improved recovery in experimental animals and pet dogs.

The research teams aimed to combine these two promising treatments into one, developing dog olfactory ensheathing cells that can create and release chondroitinase.

Injecting this new type of cell transplant into the spinal cord improved recovery of hand movements after spinal cord injury in rats. The treated subjects were shown to have increased accuracy when reaching and grasping compared to control subjects or those receiving cells alone.

Dr Jon Prager, postdoctoral researcher at the RVC, said: “Spinal cord injury causes chronic paralysis and incontinence, and remains a major worldwide healthcare burden, with no regenerative treatment clinically available. This study suggests that our genetically engineered cellular and molecular approach is a feasible combination therapy for spinal cord injury.

“Our findings show that this treatment leads to a modest improvement in rats’ ability to pick up treats and we are incredibly excited to see how the next stage of the research goes. This discovery is an exciting step in uncovering other possible combined treatments that have the potential to improve cell transplant therapy.”

Moving forward the researchers aims to test the efficacy of these treatments in ‘real-life’ injuries, such as those sustained by companion dogs and people.

The full paper is available to view here.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.